Jubilant Pharmova Ltd
NSE:JUBLPHARMA

Watchlist Manager
Jubilant Pharmova Ltd Logo
Jubilant Pharmova Ltd
NSE:JUBLPHARMA
Watchlist
Price: 1 097.4 INR 2.75% Market Closed
Market Cap: 174.8B INR
Have any thoughts about
Jubilant Pharmova Ltd?
Write Note

Jubilant Pharmova Ltd
Income to Minority Interest

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Jubilant Pharmova Ltd
Income to Minority Interest Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income to Minority Interest CAGR 3Y CAGR 5Y CAGR 10Y
Jubilant Pharmova Ltd
NSE:JUBLPHARMA
Income to Minority Interest
â‚ą42m
CAGR 3-Years
91%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Income to Minority Interest
-â‚ą862m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Income to Minority Interest
-â‚ą56.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
16%
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Income to Minority Interest
-â‚ą630.1m
CAGR 3-Years
-96%
CAGR 5-Years
34%
CAGR 10-Years
22%
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Income to Minority Interest
â‚ą0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
M
Mankind Pharma Ltd
NSE:MANKIND
Income to Minority Interest
-â‚ą288.8m
CAGR 3-Years
-2%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Jubilant Pharmova Ltd
Glance View

Market Cap
173.8B INR
Industry
Pharmaceuticals

Once rooted as a modest family business, Jubilant Pharmova Ltd. has evolved into a global powerhouse in the pharmaceutical and life sciences industry. Founded by the visionary Bhartia family, the company has sprawled across continents, transforming healthcare landscapes with its robust product portfolio. Jubilant Pharmova's journey is one painted with strategic diversification, cleverly balancing risk and driving sustainable growth. At its core, the company operates through three primary segments: Pharmaceuticals, Contract Research and Development Services, and Proprietary Drug Discovery. Each arm serves as a critical piece in the company's strategic mosaic, enhancing its resilience amid the ever-fluctuating pharmaceutical market dynamics. Underpinning Jubilant Pharmova's business model is its Pharmaceuticals segment, which churns a significant portion of its revenue. The company manufactures and sells an array of pharmaceutical products, including generics and specialty pharmaceuticals, which cater to multiple therapeutic areas. Further driving its financial engine is the Contract Research and Development Service segment, which offers outsourced R&D solutions to a host of pharmaceutical majors—a sector that has witnessed burgeoning demand alongside escalating R&D costs globally. On the innovation frontier, the Proprietary Drug Discovery segment embarks on uncharted territories, seeking novel drugs and solutions, paving the path for the future. Such a diversified approach not only positions Jubilant Pharmova as a formidable entity in the pharmaceutical domain but also provides a cushion against industry-specific headwinds, reinforcing its long-term sustainability.

JUBLPHARMA Intrinsic Value
904.27 INR
Overvaluation 18%
Intrinsic Value
Price

See Also

What is Jubilant Pharmova Ltd's Income to Minority Interest?
Income to Minority Interest
42m INR

Based on the financial report for Sep 30, 2024, Jubilant Pharmova Ltd's Income to Minority Interest amounts to 42m INR.

What is Jubilant Pharmova Ltd's Income to Minority Interest growth rate?
Income to Minority Interest CAGR 3Y
91%

Over the last year, the Income to Minority Interest growth was 8%. The average annual Income to Minority Interest growth rates for Jubilant Pharmova Ltd have been 91% over the past three years .

Back to Top